| Subject |
The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information |
- Date of occurrence of the event:2022/08/26
- Cause of occurrence:Proceeded according to the notice from Listing Supervision Department of Taipei Exchange
- Financial and business information:
(1)Monthly Account
| |
2022/7 |
2021/7 |
YoY increase/decrease(%) |
| Operating revenue(million) |
5 |
9 |
-44.44 |
| Income before income tax(million) |
(83) |
(114) |
27.19 |
| Consolidated Net Income Attributed to Stockholders of the Company(million) |
(83) |
(113) |
(26.55) |
| Earnings per share(dollar) |
(0.21) |
(0.29) |
27.59 |
(2)Accumulated over the last 2 months Account
| |
2022/6-2022/7 |
2021/6-2021/7 |
YoY increase/decrease(%) |
| Operating revenue(million) |
1,009 |
18 |
5,505.56 |
| Income before income tax(million) |
625 |
34 |
1,738.24 |
| Consolidated Net Income Attributed to Stockholders of the Company(million) |
541 |
33 |
1,539.39 |
| Earnings per share(dollar) |
1.39 |
0.09 |
1,444.44 |
(3)Quarterly Account
| |
Q2
2022
|
Q2
2021 |
YoY increase/decrease(%) |
| Operating revenue(million) |
1,017 |
13 |
7,723.08 |
| Income before income tax(million) |
434 |
(471) |
out of the red |
| Consolidated Net Income Attributed to Stockholders of the Company(million) |
338 |
(473) |
out of the red |
| Earnings per share(dollar) |
0.87 |
(1.24) |
out of the red |
- Any material information that needs to be specified according to Article 4 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities:
The subjects of the material information announced by the Company in the last six business days during August 18, 2022 to August 25, 2022 are as following details for the shareholders' reference.
(1)US FDA notified that 510(k) Premarket Notification of Bonvadis, the wound care topical cream was substantially equivalent.
(2)Oneness submitted an IND to US FDA for a phase I clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)
- Any material information in a press conference listed under Article 11 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities:None.
- Any other matters that need to be specified:
(1)The aforementioned financial information for June 2022 and July 2022 and its YOY comparison consists of the reviewed amounts prepared by the Company adopting the IFRS, and has not been audited (reviewed) by any CPA; it is only for investors' reference.
(2)The information for the last quarter (Q2 2022) refers to quarterly amounts, and has been reviewed by CPAs.
(3)The information accumulated over the last 4 quarters consists of the consolidated amounts from Q3 2021 to Q2 2022 prepared by the Company adopting the IFRS, and has been reviewed by CPAs.
(4)The net foreign exchange gain is TWD 40 million which has been recognized in July 2022.The investment loss accounted for using the equity method is TWD 90 million which has been recognized in July 2021.
(5)The investment loss accounted for using the equity method and net foreign exchange gain are TWD 111 million and TWD 124 million, respectively which have been recognized in June 2022. The investment income accounted for using the equity method is TWD 129 million which has been recognized in June 2021.
|
